National Health Laboratory Service

Generational Equity Advises Q-PLUS Labs in its Sale to Industrial Inspection & Analysis

Retrieved on: 
Friday, November 10, 2023
Other Manufacturing, Finance, Consulting, Engineering, Business, Professional Services, Manufacturing, Machinery, Machine Tools, Metalworking & Metallurgy, Sale, Acquisition, Equity, National Health Laboratory Service, IIA, ISO, Culture, Laboratory, Labs, ISO 9001:2015, Niebuhr, Typesetting

Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client Q-PLUS Labs to Industrial Inspection & Analysis, Inc. (a portfolio company of SRM Equity Partners).

Key Points: 
  • Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client Q-PLUS Labs to Industrial Inspection & Analysis, Inc. (a portfolio company of SRM Equity Partners).
  • Based in Atlanta, Georgia, Industrial Inspection & Analysis (IIA) has an extensive footprint across North America and an ever-expanding global presence in the industrial sector.
  • With the addition of Q-PLUS Labs, Industrial Inspection & Analysis has 15 locations, including nine laboratories, across North America and China.
  • We are excited to bring our expertise and culture of excellence to Industrial Inspection & Analysis,” says Mike Knicker, CEO of Q-PLUS Labs.

ENZO BIOCHEM REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 RESULTS AND PROVIDES BUSINESS UPDATE

Retrieved on: 
Monday, November 6, 2023
Sale, NYSE, National Health Laboratory Service, RNA, ENZ, Corporation, Drug development, Audit committee, Interim, Health, Enzo, Culture, GMP, Fine chemical, Video game, Retail

FARMINGDALE, NY, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fourth quarter ended July 31, 2023, and the fiscal year ended July 31, 2023, and also provided a general business update.

Key Points: 
  • FARMINGDALE, NY, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fourth quarter ended July 31, 2023, and the fiscal year ended July 31, 2023, and also provided a general business update.
  • Enzo Life Sciences’ fourth quarter revenue improved sequentially by 20%, and year over year by 13%, driven by increased demand in multiple product areas and certain key customers.
  • The Industrial market increased 48% compared to the prior year’s fourth quarter driven by the increased focus of our experienced sales team.
  • Enzo ended the fourth quarter with aggregate cash and cash equivalents and restricted cash of $83.4 million.

Pramana and Intermountain Health Collaborate to Digitize 8 Million Archival Clinical Pathology Slides Using Advanced AI Technology

Retrieved on: 
Tuesday, October 24, 2023
Technology, Biotechnology, Health, Other Health, Radiology, Artificial Intelligence, Research, Medical Devices, Software, Infectious Diseases, Hospitals, Health Technology, Science, Data Management, Digital Archives, Intermountain, National Health Laboratory Service, Marie Cassidy, Physician, Intermountain Health, Pathology, Glass, Acquisition, Multimedia, DPAA, Partnership, Hospital, Workflow, Digital pathology, Medical imaging, Pramana

As part of the agreement, Pramana will digitize approximately 8 million glass slides from Intermountain Health’s biorepository using Pramana's Spectral family of scanners and Intelligent Acquisition software .

Key Points: 
  • As part of the agreement, Pramana will digitize approximately 8 million glass slides from Intermountain Health’s biorepository using Pramana's Spectral family of scanners and Intelligent Acquisition software .
  • “Our collaboration with Intermountain Health further strengthens Pramana’s Digital Pathology as a Service (DPaaS) solution.
  • "Pramana's SpectralHT digital scanning system is now in action, digitizing our pathology slides, resulting in a notable transformation of our workflow.
  • These digital pathology slides are amplifying our research capabilities, all the while minimizing manual workload for our clinicians.”

Avalon’s Laboratory Services MSO Acquires California-Based Medical Supply Company and Proprietary FDA-Registered External Male Catheter Device

Retrieved on: 
Wednesday, September 13, 2023
Insurance, Male, Medi-Cal, Blue Cross Blue Shield Association, Aetna, MMS, National Health Laboratory Service, Durable medical equipment, LSM, CCS, Home medical equipment, MSO, FDA, Urinary incontinence, Health insurance, Medicaid, UnitedHealth Group, Humana, Medicare

Leading Edge Innovations owns the GeeWhiz External Condom Catheter, a patented, FDA-registered, in-market, male incontinence device.

Key Points: 
  • Leading Edge Innovations owns the GeeWhiz External Condom Catheter, a patented, FDA-registered, in-market, male incontinence device.
  • Notably, LSM also acquired a proprietary, FDA-registered, external male catheter device - GeeWhiz.
  • The GeeWhiz External Condom Catheter is approved for reimbursement by Medicare and a number of high-profile private insurance providers.
  • The GeeWhiz catheter device system is designed to help men with urinary incontinence and bladder control.

BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th

Retrieved on: 
Wednesday, September 6, 2023
Medical genetics, FRCP, University, Royal Free Hospital, University of the Witwatersrand, BioMarin Pharmaceutical, Consultant, Keck School of Medicine of USC, Achondroplasia, Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, University of Southern California, BMRN, Division, University of Minnesota Medical School, SAN, NHS foundation trust, Evelina London Children's Hospital, Hospital, Haemophilia, Master of Medicine, Hemostasis, Broadcasting, Instrumentation, Pediatrics, Bachelor of Medicine, Bachelor of Surgery, Endocrinology

SAN RAFAEL, Calif., Sept. 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will host an R&D Day at 8:00 a.m. ET on Tuesday, September 12, 2023. BioMarin management and external experts will provide an update to the investment community on the company's development portfolio.

Key Points: 
  • R&D Day to be Webcast Beginning at 8:00 a.m. Eastern Time September 12th
    SAN RAFAEL, Calif., Sept. 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will host an R&D Day at 8:00 a.m.
  • ET on Tuesday, September 12, 2023.
  • BioMarin management and external experts will provide an update to the investment community on the company's development portfolio.
  • An archived version of the remarks will also be available through the Company's website for a limited time following the event.

Avalon’s Laboratory Services MSO Launches Innovative Laboratory Test for Tuberculosis

Retrieved on: 
Wednesday, August 30, 2023
Infection, Culture, TB, Brain, National Health Laboratory Service, LSM, Collection, Polymerase chain reaction, Lymph, Patient, MSO, PCR, Mycobacterium tuberculosis, Disease, Vaccine, Tuberculosis, MTB

FREEHOLD, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that Laboratory Services MSO, LLC (“LSM”) is now offering an in-house laboratory developed test (“LDT”) to detect Tuberculosis (“TB”) using a patient’s sputum sample. Avalon owns a 40% interest in LSM.

Key Points: 
  • FREEHOLD, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that Laboratory Services MSO, LLC (“LSM”) is now offering an in-house laboratory developed test (“LDT”) to detect Tuberculosis (“TB”) using a patient’s sputum sample.
  • LSM’s new polymerase chain reaction (“PCR”) test allows for accurate and rapid identification of Mycobacterium tuberculosis (“Mtb”) from samples.
  • The most frequently used diagnostic methods for tuberculosis are the tuberculin skin test, acid-fast stain, culture, and polymerase chain reaction.
  • This test also has a significantly higher throughput and much lower cost per test as compared to the standard diagnostic tests.

Avalon’s Laboratory Services MSO Announces Expansion into Arizona

Retrieved on: 
Monday, August 21, 2023
Member of Congress, Barry Goldwater, Genetics, Politics, COVID-19, General Revenue Corporation, Second Continental Congress, National Health Laboratory Service, Congress, LSM, Toxicology, Republican, Genetic testing, MSO, COLA, Family, Pharmaceutical industry, Veritas

FREEHOLD, N.J., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”) is opening a new laboratory, Veritas Laboratories LLC (“Veritas”), in Scottsdale, Arizona. Avalon owns a 40% interest in LSM. Veritas is a CLIA-certified and COLA-accredited laboratory that offers a wide range of high-quality testing, including drug testing, genetic testing, urinary testing and COVID-19 PCR testing.

Key Points: 
  • New Wholly Owned Lab “Veritas Laboratory” of Arizona, Anticipated to Generate Revenue in 2023
    Engages Former Congressman Barry M. Goldwater Jr. To Expand Insurance Coverage and Grow Lab Footprint
    FREEHOLD, N.J., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”) is opening a new laboratory, Veritas Laboratories LLC (“Veritas”), in Scottsdale, Arizona.
  • Veritas is a CLIA-certified and COLA-accredited laboratory that offers a wide range of high-quality testing, including drug testing, genetic testing, urinary testing and COVID-19 PCR testing.
  • Additionally, LSM has engaged former Congressman Barry M. Goldwater to expand coverage with in-network providers and grow laboratory footprint in Arizona.
  • Congressman Barry M. Goldwater, Jr. stated, “We welcome LSM to Arizona as they open a new facility in Scottsdale.

Avalon’s Laboratory Services MSO Acquires Texas Lab with Significant Potential Growth

Retrieved on: 
Monday, July 24, 2023
COVID-19, National Health Laboratory Service, LSM, Acquisition, Laboratory, Genetic testing, MSO, COLA, Pharmaceutical industry, Fine chemical

FREEHOLD, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”), has acquired DE Laboratory LLC (“DE Labs”), which expands its penetration within Texas and provides significant potential growth opportunities for the combined company.

Key Points: 
  • FREEHOLD, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”), has acquired DE Laboratory LLC (“DE Labs”), which expands its penetration within Texas and provides significant potential growth opportunities for the combined company.
  • LSM is now operating this laboratory as a fully owned subsidiary and has invested growth capital for geographical expansion into the surrounding counties.
  • “Our strategy is to take advantage of a unique roll-up opportunity within the highly fragmented market for laboratory testing and services.
  • By leveraging LSM’s experience and infrastructure, we expect to achieve significant synergies with respect to revenue growth and market share.”

Avalon GloboCare’s Laboratory Services MSO Signs Exclusive In-Network Lab Services Agreement Providing Significant Expansion Opportunity into 21 States

Retrieved on: 
Wednesday, July 19, 2023
Aetna, CAP, COVID-19, Genex Power, Genetic testing, Cigna, National Health Laboratory Service, Medicare, LSM, MSA, Laboratory, Master service agreement, Others, LC-MS, Instrumental chemistry, MSO, UnitedHealth Group, Toxicology testing, Pharmaceutical industry, Medicaid

FREEHOLD, N.J., July 19, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”), has signed an exclusive Master Service Agreement (“MSA”) with GeneX Laboratory Professional Corp. (“GeneX”). Avalon owns a 40% interest in LSM.

Key Points: 
  • Genex is a CLIA-certified and CAP-accredited laboratory located in Orange County, California that has been dormant and seeking a partner to utilize their valuable license networks.
  • Those tests will now be performed utilizing the LSM infrastructure and resources providing significant expansion opportunity for LSM to perform services through in-network insurance providers previously unavailable.
  • GeneX provides top-tier, comprehensive laboratory testing services and works with major providers in addition to Medicaid in 21 states.
  • By leveraging LSM’s experience and infrastructure, we expect to achieve significant synergies with respect to revenue growth and market shares,” concluded Dr. Jin.

AdventHealth Wesley Chapel Enhances Cancer Testing Speed, Accuracy with Cutting-Edge Lab Technology

Retrieved on: 
Thursday, July 13, 2023
Uncertainty, Surgeon, Multimedia, National Health Laboratory Service, Patient, Physician, Blood, Workload, Oncology, Counselor, Hospital, Microscope

WESLEY CHAPEL, Fla., July 13, 2023 /PRNewswire/ -- AdventHealth Wesley Chapel is significantly reducing the turnaround time for cancer test results with the recent purchase of cutting-edge technology for its hematology department. This addition to the lab is thanks to the AdventHealth Wesley Chapel Foundation, which provided more than $400,000 in donations.

Key Points: 
  • WESLEY CHAPEL, Fla., July 13, 2023 /PRNewswire/ -- AdventHealth Wesley Chapel is significantly reducing the turnaround time for cancer test results with the recent purchase of cutting-edge technology for its hematology department.
  • This addition to the lab is thanks to the AdventHealth Wesley Chapel Foundation, which provided more than $400,000 in donations.
  • AdventHealth Wesley Chapel expanded its oncology services just over two years ago, recognizing the increasing and crucial need for cancer treatment in the county.
  • Funds that our patients and supporters donate to the Wesley Chapel Foundation directly support our programs, facility, and patients right here in Wesley Chapel" said Erik Wangsness, President, and CEO at AdventHealth Wesley Chapel.